New drug combo aims to boost lymphoma treatment
NCT ID NCT07097363
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding epcoritamab, a bispecific antibody that helps the immune system attack cancer cells, to standard chemotherapy (EPOCH-R) is safe and effective for aggressive B-cell non-Hodgkin lymphoma. About 18 patients with hard-to-treat forms of the disease will receive the combination. The study will monitor side effects and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- epcoritamab (a bispecific antibody) plus chemotherapy (EPOCH-R)
- What this could lead to
- If successful, this combination could offer a more effective upfront treatment for aggressive B-cell lymphomas that don't respond well to standard therapy.
- What could go wrong
- This is a small, early-phase pilot study with only 18 participants. Side effects from adding a new drug to chemotherapy are unknown, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard chemo for an aggressive lymphoma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them